)
DRI Healthcare Trust (DHT-UN) investor relations material
DRI Healthcare Trust Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved strong Q3 results with double-digit growth in cash receipts, income, and adjusted EBITDA, led by Orserdu, Xolair, and Rydapt, and supported by portfolio diversification and resilient cashflow streams.
Completed internalization of investment management, paying a $48 million termination fee and acquiring assets from Persis Capital for $1 million.
Completed a synthetic royalty transaction on veligrotug and VRDN-003 for up to $300 million, with $55 million upfront and up to $115 million in milestone payments, expanding exposure to the TED market.
Continued execution of NCIB program, repurchasing over 4.5 million units as of September 30, 2025, to enhance unitholder value.
EKTERLY approval in July marked a milestone, with royalties beginning on a one-quarter lag and a $22 million payment increasing royalty entitlement.
Financial highlights
Q3 2025 total cash receipts: $43.6 million, up 12% year-over-year; total income: $48.7 million, up 17% year-over-year.
Adjusted EBITDA: $36.7 million (84% margin), up 17% year-over-year; last twelve months adjusted EBITDA: $155.7 million (82% margin).
Adjusted cash earnings per unit: $0.55 for Q3 2025; $2.25 for the last 12 months.
Cash and equivalents: $35.6 million; royalties receivable: $52.9 million; credit facility availability: $265.4 million as of September 30, 2025.
Declared cash distributions of $0.10 per unit for the quarter.
Outlook and guidance
Robust pipeline of over $3 billion in potential opportunities under active evaluation as of September 30, 2025.
Guidance for total income CAGR to be updated in Q4, with management expressing confidence in current trajectory.
Anticipates first royalty receipts from veligrotug following its first US commercial sale and expects topline results from VRDN-003 phase 3 trials in H1 2026.
Expects gradual recovery in Omidria sales into 2026 and continued growth for Vonjo, despite impairment.
Focus remains on long-term, sustainable growth and generating strong unitholder returns.
Next DRI Healthcare Trust earnings date
Next DRI Healthcare Trust earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage